Comparing two blood thinners for kidney dialysis in sepsis
Treatments studied
Part of Infections, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests two blood thinners (nafamostat and heparin) during kidney dialysis for people with sepsis-related acute kidney injury. The goal is to find which is safer and works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 90 years old.
- You have sepsis (a severe infection) or septic shock.
- You have acute kidney injury (stage 2 or 3).
- You have been on kidney dialysis for at least 24 hours.
- You are expected to live at least 48 more hours.
- You do not have a bleeding problem or active bleeding.
- You do not have pre-existing chronic kidney disease or are not already on regular dialysis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different blood-thinning methods used during continuous kidney-support treatment (CRRT) for patients who have developed severe kidney injury due to sepsis. The goal is to see which method works better and is safer for patients in this critical condition.
This trial tests a medication called nafamostat mesilate to help control blood clotting problems caused by severe infections (sepsis). It may be an option for people with sepsis who are at risk of bleeding but do not have active bleeding.
This trial tests whether a special type of dialysis filter (oXiris) helps reduce blood clotting problems in patients with septic shock and kidney failure. It may offer a better option for those needing kidney support in the ICU.
This trial tests if a drug called nafamostat mesylate can help people with sepsis who have blood clotting problems and need a special type of kidney treatment (hemofiltration). It may improve their chances of recovery.
This trial is testing different doses of a blood thinner called nafamostat in patients who are in the ICU and need continuous kidney dialysis (CRRT). The goal is to find which dose works best to prevent clots in the dialysis machine without causing bleeding problems.
This trial tests a new medicine called nafamostat to prevent blood clots during continuous dialysis (CRRT), for people who are at high risk of bleeding or can't take heparin.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.